GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (FRA:ANWA) » Definitions » 10-Year RORE %

Immuron (FRA:ANWA) 10-Year RORE % : 0.00% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Immuron 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Immuron does not have enough data to calculate 10-Year RORE %.


Immuron 10-Year RORE % Historical Data

The historical data trend for Immuron's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron 10-Year RORE % Chart

Immuron Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only - - - - -

Immuron Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immuron's 10-Year RORE %

For the Biotechnology subindustry, Immuron's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immuron's 10-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuron's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Immuron's 10-Year RORE % falls into.



Immuron 10-Year RORE % Calculation

Immuron's 10-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( - )/( - )
=/
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 10-year before.


Immuron  (FRA:ANWA) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Immuron 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Immuron's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuron (FRA:ANWA) Business Description

Traded in Other Exchanges
Address
Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (FRA:ANWA) Headlines

No Headlines